Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.

Spencer, Andrew; Samoilova, Olga; Chng, Wee-Joo; Labotka, Richard; Li, Cong; Wu, Kwang-Wei; Saxena, Nakul; Yan, Xu; Lee, Jae Hoon; Beksac, Meral

Spencer, Andrew; Samoilova, Olga; Chng, Wee-Joo; Labotka, Richard; Li, Cong; Wu, Kwang-Wei; Saxena, Nakul; Yan, Xu; Lee, Jae Hoon; Beksac, Meral.

Afiliação

Spencer A; The Alfred Hospital-Monash University Melbourne Victoria Australia.
Samoilova O; State Budget Institution of Healthcare of Nizhny Novgorod Region Nizhny Novgorod Regional Clinical Hospital Nizhny Novgorod Russia.
Chng WJ; National University Hospital Singapore Singapore.
Labotka R; Takeda Development Center Americas Lexington Massachusetts USA.
Li C; Takeda Development Center Americas Lexington Massachusetts USA.
Wu KW; Takeda Pharmaceuticals International AG Singapore Singapore.
Saxena N; Takeda Pharmaceuticals International AG Singapore Singapore.
Yan X; State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin China.
Lee JH; Gachon University Gil Medical Center Namdong-gu South Korea.
Beksac M; Department of Hematology Ankara University School of Medicine Dikimevi Turkey.

EJHaem ; 3(4): 1241-1251, 2022 Nov.

Article em En | MEDLINE | ID: mdl-36467842

Palavras-chave

emergingmarkets; ixazomib; multiple myeloma; overall survival; proteasome inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: EJHaem Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google